QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.004721v1 33/7/892    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Herwaarden, A. E. Articles by Schinkel, A. H. Search for Related Content PubMed PubMed Citation Articles by van Herwaarden, A. E. Articles by Schinkel, A. H.

SHORT COMMUNICATION

MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4

Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam (A.E.v.H., J.W.S., E.W., C.M.M.v.d.K., J.H.M.S., A.H.S.); Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam (J.H.B.); and Department of Biomedical Analysis, Utrecht University, Utrecht (R.W.S.), The Netherlands

Cytochrome P450 3A4 (CYP3A4) is a major determinant of the metabolism of many drugs, including important anticancer drugs, with sometimes profound impact on therapeutic efficacy and toxic side effects. To study in vivo CYP3A(4) functions, we have generated and characterized transgenic mice with functional expression of human CYP3A4 cDNA in the liver. Two transgenic lines displayed substantial, physiologically relevant and stable CYP3A4 levels in liver and moderate levels in kidney, but not in small intestine. The mice did not display obvious physiological abnormalities. The CYP3A4 substrate drugs midazolam and cyclosporin A were used to test functional activity of CYP3A4 in liver. The area under the plasma concentration versus time curve (AUC) of intravenously administered midazolam (30 mg/kg) was 2.2-fold decreased in the transgenic mice compared with wild-type (5.45 ± 0.21 versus 11.7 ± 0.46 µg · hml^–1; P < 0.01), and early formation of the primary metabolite 1-hydroxymidazolam was about 2-fold increased, demonstrating the functionality of CYP3A4 in the liver. Similarly, following intravenous administration of cyclosporin A (20 mg/kg), CYP3A4 transgenic mice displayed a reduced plasma AUC compared with wild-type (24.3 ± 0.66 versus 35.8 ± 0.53 µg · hml^{– 1}; P < 0.01). Thus, midazolam and cyclosporin A, compounds with markedly different clearance rates and half-lives, both demonstrated clearly accelerated kinetics in the CYP3A4 transgenic mice. We expect that this CYP3A4 transgenic model will provide a useful tool to study the impact of CYP3A4 on drug levels, especially when combined with other transgenic and knockout strains.

This article has been cited by other articles:

				E. van de Steeg, C. M.M. van der Kruijssen, E. Wagenaar, J. E.C. Burggraaff, E. Mesman, K. E. Kenworthy, and A. H. Schinkel Methotrexate Pharmacokinetics in Transgenic Mice with Liver-Specific Expression of Human Organic Anion-Transporting Polypeptide 1B1 (SLCO1B1) Drug Metab. Dispos., February 1, 2009; 37(2): 277 - 281. [Abstract] [Full Text] [PDF]

				C. Cheung and F. J. Gonzalez Humanized Mouse Lines and Their Application for Prediction of Human Drug Metabolism and Toxicological Risk Assessment J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 288 - 299. [Abstract] [Full Text] [PDF]

				R. A. B. van Waterschoot, A. E. van Herwaarden, J. S. Lagas, R. W. Sparidans, E. Wagenaar, C. M. M. van der Kruijssen, J. A. Goldstein, D. C. Zeldin, J. H. Beijnen, and A. H. Schinkel Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes Mol. Pharmacol., March 1, 2008; 73(3): 1029 - 1036. [Abstract] [Full Text] [PDF]

				M. A. Felmlee, H.-K. Lon, F. J. Gonzalez, and A.-M. Yu Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice Drug Metab. Dispos., February 1, 2008; 36(2): 435 - 441. [Abstract] [Full Text] [PDF]